A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
This important study is looking into a new tablet called losmapimod for adults living with Facioscapulohumeral Muscular Dystrophy (FSHD). FSHD is a condition that causes muscle weakness, often in the face, shoulders, and upper arms. The main goal is to find out if losmapimod can help improve how well people can use their arms, specifically looking at wrist movement, after about a year of treatment. Researchers also want to understand if the medication is safe and well-tolerated when taken for a longer period. Participants will be given either the active drug or a dummy tablet (placebo) to ensure a fair test, and neither the participants nor their doctors will know who is getting which. The study will last for 48 weeks, making sure to track any changes in muscle strength and overall well-being.
במבט חטוף
על מה המחקר הזה?
This study, called REACH, is a significant worldwide research project investigating a new medication called losmapimod. It's designed for people who have Facioscapulohumeral Muscular Dystrophy, or FSHD. FSHD is a genetic condition that causes muscles to weaken and waste away over time, often starting in the face, shoulders, and upper arms.
The main purpose of this study is to see if losmapimod, taken as a tablet, can help improve how people use their arms, particularly focusing on wrist movements, after about a year of treatment. The researchers will also be closely watching to make sure the medication is safe to use and doesn't cause too many side effects over a longer period. To get reliable results, some participants will receive the active drug, while others will receive a 'dummy' tablet that looks identical to the real one. This approach, called 'double-blind,' means that neither you nor your study doctor will know whether you're getting the active treatment or the dummy tablet until after the study is complete. This helps to make sure the results are as unbiased as possible.
This type of study, known as 'Phase 3,' is usually the last step before a new medicine can be considered for approval. It means that earlier studies have shown some promise, and now the researchers need to confirm these findings in a larger group of people. The information gathered from this study will be crucial in understanding whether losmapimod could become a new treatment option for people with FSHD.
נקודות עיקריות
- This study evaluates a potential new tablet treatment (losmapimod) for FSHD.
- It aims to see if the drug improves arm function and is safe over nearly a year.
- Participants will receive either the active drug or a dummy tablet (placebo).
- It's a large, global study, so the results will be very important.
- Participation involves regular clinic visits for checks, tests, and assessments.
- All adults with FSHD (age 18+) are welcome to check if they are eligible.
מי עשוי להיות זכאי?
The study is looking for adults who have been diagnosed with Facioscapulohumeral Muscular Dystrophy (FSHD). You must be at least 18 years old to take part; there is no upper age limit, meaning older adults are also welcome to participate.
Participants can be of any sex – both men and women are invited to join the study if they meet the other requirements. The most important thing is that you have a confirmed diagnosis of FSHD.
האם מחקר זה יכול להתאים לך?
ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.
- I have been diagnosed with Facioscapulohumeral Muscular Dystrophy (FSHD).
- אני בן 18 או יותר.
- I am able to attend regular clinic appointments.
- I am living in the UK and can travel to a study site.
- I am willing to take a tablet twice a day for nearly a year.
- I am comfortable with my study team and I not knowing if I am taking the active drug or a dummy tablet.
מה כרוך בהשתתפות?
If you decide to take part in this study, you would primarily be taking a tablet, either the study drug (losmapimod) or a placebo (a dummy tablet), twice a day for 48 weeks (around 11 months). You wouldn't know which one you are taking. You would have regular visits to the study clinic where the medical team would: perform physical examinations; check your vital signs (like blood pressure and heart rate); take blood samples for lab tests; measure your arm and shoulder strength with special tools; and ask you to fill out questionnaires about your well-being and how you feel your condition is changing. There will also be assessments of your arm function, such as how you move your wrist with a small weight. Your heart activity will be monitored with ECGs (heart tracings). After the 48 weeks, there might be a follow-up period to check on your health.
סיכונים ותועלות פוטנציאליים
מיקומים (6)
- —לא מאומתאיטליה
- —לא מאומתספרד
- —לא מאומתצרפת
- —לא מאומתגרמניה
- —לא מאומתהולנד
- —לא מאומתדנמרק
שאלות נפוצות
What is FSHD?
FSHD stands for Facioscapulohumeral Muscular Dystrophy. It's a genetic condition that causes muscles to weaken over time, often affecting the face, shoulders, and upper arms.
What is losmapimod?
Losmapimod is a new drug being tested in this study. It's a tablet you take by mouth, and researchers want to see if it can help people with FSHD.
מה המשמעות של 'פלצבו'?
A placebo is a 'dummy' tablet that looks exactly like the actual study drug but contains no active medicine. It helps researchers fairly compare how well the real drug works.
כמה זמן יימשך המחקר?
The main treatment part of the study will last for 48 weeks, which is almost a year. There might be some follow-up appointments after that.
האם אדע אם אני מקבל את התרופה האמיתית או את הפלצבו?
No, neither you nor your study doctor will know if you're taking losmapimod or the placebo until after the study is finished. This is to ensure the results are unbiased.
כיצד לגלות עוד
תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.
מעוניינים להשתתף?
דיון
דיון קהילתי
מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.